

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
5th January, 2026

Yoshiyuki Tanaka appointed Chief Medical Officer (CMO)

Chordia Therapeutics Inc (“Chordia”), is pleased to announce the appointment of Yoshiyuki Tanaka as Chief Medical Officer (“CMO”). With the appointment of Yoshiyuki Tanaka, the Company will further strengthen its clinical development capabilities and advance the U.S. clinical trial of rogocekib swiftly and reliably.

Profile of Yoshiyuki Tanaka, CMO

Yoshiyuki Tanaka	Oct 1998	Washington University School of Medicine in St. Louis, USA
	Nov 2005	Research Fellow, Biologic Cancer Therapy Program MSD K.K. (formerly Banyu Pharmaceutical Co., Ltd.) Served as Head of Clinical Research Division and Head of Oncology Science Unit, Global Research & Development Division
	Jul 2025	Chordia Therapeutics Inc, Medical Expert
	Jan 2026	CMO

Comment from Hiroshi Miyake, CEO

We are delighted to announce the appointment of Dr. Yoshiyuki Tanaka as CMO of our company. After obtaining his medical license, Dr. Tanaka engaged in clinical practice and cancer research in Japan, followed by study at the Washington University School of Medicine in St. Louis, USA. Upon returning to Japan, he joined MSD K.K., the Japanese subsidiary of Merck & Co., Inc., where he contributed to the development of innovative pharmaceuticals for approximately two decades across a wide range of therapeutic areas, including vaccines, infectious diseases, and oncology. He played a key role in bringing a number of medicines to market. Most recently, as Head of Oncology Clinical Development at MSD, he led oncology drug development in Japan under the company’s global strategy. Dr. Tanaka joined Chordia as a medical expert on July 1, 2025. Chordia’s ongoing Phase 1/2 clinical trial of rogocekib in the United States is currently at a critical stage. With Dr. Tanaka’s appointment as CMO at this pivotal moment, Chordia will further strengthen its clinical development organization and deepen collaboration with U.S. investigators, thereby accelerating and ensuring steady progress in the development of rogocekib. Leveraging Dr. Tanaka’s extensive expertise in clinical development and regulatory affairs, Chordia will also advance preparations for future regulatory submissions with the highest level of rigor. His appointment marks an important milestone for Chordia as the company continues to pursue further growth and the creation of innovative therapeutics.

Comment from Yoshiyuki Tanaka, CMO

I am deeply honored to serve as CMO of Chordia, a company originating from Japan that is pioneering novel first-in-class pipelines of anticancer therapies. To deliver innovative treatments to patients suffering from cancer in better and faster way, I will fully leverage my experience in global clinical development and regulatory strategy to accelerate the advancement of our programs. Furthermore, I will ensure steady preparation for future regulatory submissions and work to enhance Chordia's corporate value, thereby contributing to patients and all of our stakeholders.

About Chordia Therapeutics

Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including CTX-177, a MALT1 inhibitor, CTX-439, a CDK12 inhibitor, and GCN2 inhibitors.

Established: November 2017
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Representative: Hiroshi Miyake, Representative Director
Website: <https://www.chordiatherapeutics.com/en/>

For more information, contact, IR Kira: ir@chordiatherapeutics.com